Author/Authors :
Bazrgari, Farzaneh School of Pharmacy - Mashhad University of Medical Sciences, Mashhad, Iran , Khameneh, Bahman School of Pharmacy - Mashhad University of Medical Sciences, Mashhad, Iran , Fazly Bazzaz, Sedigheh Biotechnology Research Center - Pharmaceutical Technology Institute - Mashhad University of Medical Sciences, Mashhad, Iran , Mahmoudi, Asma School of Pharmacy - Mashhad University of Medical Sciences, Mashhad, Iran , Malaekeh-Nikouei, Bizhan Nanotechnology Research Center - Pharmaceutical Technology Institute - Mashhad University of Medical Sciences, Mashhad, Iran
Abstract :
Objective(s): Staphylococcus epidermidis is a common cause of medical device-associated infections due to biofilm formation, and its elimination is extremely challenging. Although rifampin efficacy against S. epidermidis biofilms has been confirmed, its use as a single agent may lead to resistance. As such, it
is assumed that the combination of rifampin and N-acetylcysteine (NAC) could exert additive effects as a mucolytic agent. The present study aimed to use a liposomal system for the delivery of these compounds to bacterial biofilm.
Materials and Methods: Liposomal formulations were prepared using the dehydration-rehydration method and characterized in terms of the size, zeta potential, and encapsulation efficacy. In addition, the ability of various formulations in the eradication of bacterial biofilm and inhibition of biofilm formation was assessed
based on the optical density ratio.
Results: The zeta potential of the liposomes was positive, and the mean size of these liposomal formulations was less than 200 nanometers. Liposomal rifampin was the most effective formulation against S. epidermidis, and the anti-biofilm activity of most of the formulations was concentration-dependent and time-dependent.
Conclusion: According to the results, the rifampin-loaded liposomes were effective against S. epidermidis biofilm formation.
Keywords :
Biofilm , Nanoliposomes , N-acetyl cysteine , Rifampin